Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Senaparib First-line Maintenance in Advanced Ovarian/FT/Primary Peritoneal Cancer
ChiCTR2600129532Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of senaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Progression-free Survival and Overall Survival. Started Aug 2026; status: recruiting.
02
Drugs
senaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600129532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129532.